Phase II trial of oral vinorelbine in Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC) patients with Epidermal Growth Factor Receptor (EGFR) positive mutation after failure or resistance to treatment with Tyrosine Kinase Inhibitors
Phase II trial of oral vinorelbine in Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC) patients with Epidermal Growth Factor Receptor (EGFR) positive mutation after failure or resistance to treatment with Tyrosine Kinase Inhibitors
NAVOTRIAL 2
Phase II trial of oral vinorelbine in Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC) patients with Epidermal Growth Factor Receptor (EGFR) positive mutation after failure or resistance to treatment with Tyrosine Kinase Inhibitors (TKI) in first line
Statut
Status :
Terminé
Type d'étude
Phase II
Age Min.
18
Ans
Age Max.
85
Ans
Genre
Tous
Aire thérapeutique :
Oncologie
Maladie :
Cancer du poumon métastatique non à petites cellules
Traitement :
Vinorelbine (Navelbine® Oral)
Phase :
Phase II
Date de début de l'étude :
01 Décembre 2012
End date :
17 Avril 2015
Identifiant de l'essai :
PM0259 CA 229 J1
Identifiant EudraCT/CTIS :
2012-003361-18
Envoyer par email